ArticleTargeted oncology2023

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.

Todd M Bauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.